Want to see TSE:MDMA full AI Analyst Report?
PharmAla Biotech Holdings, Inc. (MDMA) Income Statement
PharmAla Biotech Holdings, Inc. Income Statement
Last quarter (Q3 2026), PharmAla Biotech Holdings, Inc.'s total revenue was $513.23K, an increase of 279.70% from the same quarter last year. In Q3, PharmAla Biotech Holdings, Inc.'s net income was $-499.76K. See PharmAla Biotech Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Nov 25 | Nov 24 | Nov 23 | Nov 22 | Aug 21 |
|---|---|---|---|---|---|
| $ 605.50K | $ 1.04M | $ 532.00K | $ 78.07K | $ 0.00 | |
| $ -845.17K | $ 887.44K | $ 454.10K | $ 75.78K | $ -303.00 | |
| $ 1.31M | $ 1.53M | $ 1.22M | $ 1.06M | $ 2.51M | |
| Depreciation and Amortization | $ 117.05K | $ 70.21K | $ 52.77K | $ 12.13K | $ 303.00 |
| $ -2.07M | $ -573.36K | $ -710.18K | $ -973.45K | $ -2.51M | |
| $ -2.15M | $ -643.57K | $ -762.95K | $ -985.58K | $ -2.51M | |
| $ -22.02K | $ -180.03K | $ -16.86K | $ 0.00 | $ 0.00 | |
| $ -2.18M | $ -823.60K | $ -779.81K | $ -985.58K | $ -2.51M | |
| $ -2.18M | $ -823.60K | $ -779.81K | $ -985.58K | $ -2.51M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.02 | $ -0.01 | $ -0.01 | $ -0.01 | $ -0.03 |
| Diluted EPS | $ -0.02 | $ -0.01 | $ -0.01 | $ -0.01 | $ -0.03 |
| Weighted Average Shares Outstanding | 99.58M | 88.57M | 84.53M | 83.00M | 83.00M |
| Weighted Average Shares Outstanding (Diluted) | 99.58M | 88.57M | 84.53M | 83.00M | 83.00M |
Currency in CAD